

**AMENDMENTS TO THE CLAIMS**

1. – 7. (Cancelled)

8. (Currently amended) A method for treating an animal with a Th1 or Th2 related disease by administering a helminthic parasite preparation that alters a regulatory T cell activity to said animal; and determining the level of regulatory T cell activity, ~~wherein an increase in regulatory T cell activity after said administering is indicative of successful treatment.~~

9-16. (Cancelled)

17. (Previously presented) The method of claim 8, wherein said regulatory T cell activity is measured by determining the level of a regulatory T cell marker.

18. (Previously presented) The method of claim 17, wherein said regulatory T cell marker is an internal marker.

19. (Previously presented) The method of claim 18, wherein said internal marker is Scurfin, Smad7, Gata3, or Tbet (Tbx21) .

20. (Previously presented) The method of claim 17, wherein said regulatory T marker is a cell surface marker.

21. (Previously presented) The method of claim 20, wherein said cell surface marker is selected from the group consisting of: CD4, CD45RB<sup>lo</sup>, CD45Rc, Cytotoxic T lymphocyte associated antigen 4 (CTLA-4), Ox40, 4-1BB, CD25, CD103, CD62L,  $\alpha_E\beta$  integrin, latency-associated peptide (LAP) or glucocorticoid induced TNF receptor family related protein (GITR), chemokine receptor CCR5, TI-ST2.

22. (Previously presented) The method of claim 17, wherein said regulatory T cell marker is a secreted marker.

23. (Previously presented) The method of claim 22, wherein said secreted marker is IL4, IL13, IL-5, IL-10 or TGF $\beta$ , PgE2.